Kezar Life Sciences Business Summary

Kezar Life Sciences, Inc. (KZR) is a clinical-stage biopharmaceutical company that generates value through the development of novel small molecule therapeutics, primarily targeting the immunoproteasome and protein secretion pathways. As of early 2026, the company reports zero product revenue, operating as a pre-commercial entity focused on its two primary business segments: Autoimmunity and Oncology. Following a significant strategic restructuring in late 2025 that reduced its workforce by approximately 70%, Kezar has pivoted to a lean operational model to maximize its remaining cash runway while exploring strategic alternatives, including potential mergers or asset divestitures. Its lead candidate, zetomipzomib, is currently positioned for the treatment of autoimmune hepatitis (AIH) following the discontinuation of its lupus nephritis program. Kezar operates within a highly specialized competitive landscape alongside firms such as Arvinas, Agios Pharmaceuticals, Celldex Therapeutics, and Cartesian Therapeutics, distinguishing itself through its unique focus on selective immunoproteasome inhibition for rare, refractory immune-mediated diseases. Kezar was co-founded by Dr. Christopher Kirk, John Fowler, and Dr. Jack Taunton, leveraging a pedigree rooted in successful proteasome inhibitor development at Onyx Pharmaceuticals and Proteolix. The leadership team is currently headed by CEO and Co-Founder Christopher Kirk, PhD, an immunologist who previously served as the company’s Chief Scientific Officer and played a pivotal role in the discovery of carfilzomib. He is supported by Marc Belsky, Chief Financial Officer, who brings extensive biopharmaceutical finance experience from Five Prime Therapeutics, and Mark Schiller, Chief Operating Officer, who oversees legal and operational strategy. The company’s board is chaired by Graham Cooper and includes co-founder John Fowler, while its institutional investor base features prominent life science specialists such as Cormorant Asset Management, EcoR1 Capital, and Morningside Venture Investments.